Arcutis Biotherapeutics (ARQT) vs Arcus Biosciences (RCUS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Arcus Biosciences (RCUS) has outperformed Arcutis Biotherapeutics (ARQT) over the past year, gaining 74.8% versus a gain of 17.5%. Over five years, ARQT leads with a +8.5% price change compared with -28.7% for RCUS. Arcus Biosciences is the larger company by market cap ($3.08 billion vs $3.04 billion), about 1.0 times the size, while Arcutis Biotherapeutics is growing revenue faster (+91.3% vs -4.3%).
Arcutis Biotherapeutics converts more of its revenue into profit, with a net margin of -4.3% versus -142.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARQT | RCUS |
|---|---|---|
| Share price | $24.17 | $24.52 |
| Market cap | $3.04B | $3.08B |
| 1-day change | +1.05% | +0.99% |
| YTD return | -16.77% | +2.90% |
| 1-year return | +17.50% | +74.77% |
| 5-year return | +8.48% | -28.70% |
| P/E ratio (TTM) | 109.86 | — |
| Forward P/E | 17.77 | — |
| EPS (TTM) | $0.22 | $-3.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $376.07M | $247.00M |
| Revenue growth (YoY) | +91.34% | -4.26% |
| Net income (latest FY) | $-16.14M | $-353.00M |
| Gross margin | 90.24% | — |
| Operating margin | -3.25% | -156.28% |
| Net margin | -4.29% | -142.91% |
| 52-week high | $31.77 | $31.74 |
| 52-week low | $19.30 | $14.26 |
| Distance from 52-week high | -23.92% | -22.74% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +53.08% | +62.77% |
| Average volume | 2.22M | 1.32M |
| Shares outstanding | 125.69M | 125.77M |
| Employees | 354 | 601 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RCUS has outperformed ARQT by 57.3 percentage points over the past year.
- Arcutis Biotherapeutics is more profitable, keeping -4.3 cents of every revenue dollar as net income versus -142.9 cents for Arcus Biosciences.
- Arcutis Biotherapeutics grew revenue faster in its latest fiscal year (+91.34% vs -4.26%).
About Arcutis Biotherapeutics
ARQT stock →Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 354 employees
About Arcus Biosciences
RCUS stock →Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees
ARQT vs RCUS FAQ
Which is bigger, Arcutis Biotherapeutics or Arcus Biosciences?
Arcus Biosciences (RCUS) is larger, with a market capitalization of $3.08B compared with $3.04B for Arcutis Biotherapeutics (ARQT).
Which stock has performed better over the past year, ARQT or RCUS?
RCUS returned +74.77% over the past 12 months, compared with +17.50% for ARQT (price return, excluding dividends). Past performance does not predict future results.
Are Arcutis Biotherapeutics and Arcus Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.